AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31506080
Drug: Novel FSHD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel FSHD functional composite COA made up of 18 evaluator-administered motor tasks in the domains of shoulder/arm, hand, core/abdominal, leg, and balance function
Trial: 31506080
Drug: Orofacial strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orofacial strength using the Iowa Oral Performance Instrument
Trial: 31506385
Drug: Dabrafenib (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabrafenib (specific dosage and duration not provided)
Trial: 31506387
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine (Rova-T) 0.3 mg/kg once every 6 weeks for two cycles
Trial: 31507322
Drug: Other Atypical
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Atypical Antipsychotics (AAPs)
Trial: 31508232
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education intervention (three educational sessions over a six-week period)
Trial: 31508518
Drug: Ibrutinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (50 mg/kg p.o daily for three weeks)
Trial: 31512728
Drug: iscalimab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iscalimab (10 mg/kg intravenously over 12 weeks)
Trial: 31513018
Drug: Chemoimmunotherapy (CIT)
RxNorm normalized name: Cit
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy (CIT) with oregovomab (anti-CA-125), gemcitabine/leucovorin/fluorouracil for 3 cycles, followed by nelfinavir (1250 mg bid for 5 weeks) and SBRT (40 Gy/5 fractions) during the third week of nelfinavir.
Trial: 31513018
Drug: Oregovomab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oregovomab (2 mg) administered for 7 total doses (3 pre-SBRT, 1 between SBRT and resection, and 3 postoperatively)
Trial: 31514508
Drug: Obstructive Sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstructive Sleep Apnea (OSA) treatment, specific intervention details not available
Trial: 31515828
Drug: GHX02 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHX02 at 0, 1250, 2500, and 5000 mg/kg/day for 28 days
Trial: 31516727
Drug: Eccentric exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric exercise plus manual therapy
Trial: 31516734
Drug: Eplerenone 50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg/day for 4 weeks
Trial: 31518254
Drug: Photo story
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Photo story in tablet format
Trial: 31518254
Drug: Traditional brochure
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional brochure in tablet format
Trial: 31519196
Drug: Low-dose chest
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chest CT (LDCT) and circulating tumor cells (CTC) search on a blood sample, followed by two additional screening rounds at one-year intervals.
Trial: 31519676
Drug: Community-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based exercise (minimum of 60 min of mild-to-moderate intensity full body exercise twice weekly for a 12-week period)
Trial: 31520559
Drug: Aflibercept (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (4 mg/kg) plus FOLFIRI every 2 weeks
Trial: 31520559
Drug: Pre-dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-dose 3 levels of biomarkers
Trial: 31521128
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy (PAC)
Trial: 31521134
Drug: 3 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of FOLFIRINOX neoadjuvant chemotherapy followed by a short-course of carbon ion radiotherapy (CIRT)
Trial: 31521574
Drug: Central augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central augmentation index
Trial: 31523049
Drug: Anticitrullinated protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticitrullinated protein antibody/rheumatoid factor positivity
Trial: 31523279
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (clarithromycin, metronidazole, levofloxacin)
Trial: 31523279
Drug: Empirical amoxicillin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical amoxicillin-containing bismuth quadruple therapy
Trial: 31524342
Drug: ATX-101 (deoxycholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX-101 (deoxycholic acid) 2 mg/cm2
Trial: 31525774
Drug: Blood cultures
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood cultures obtained before initiation of antimicrobial treatment
Trial: 31525774
Drug: Blood cultures
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood cultures obtained within 120 minutes after initiation of antimicrobial treatment
Trial: 31527689
Drug: Plasma EBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma EBV DNA-negative patients (0-20 copies/ml)
Trial: 31527689
Drug: Plasma EBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma EBV DNA-positive patients (>20 copies/ml)
Trial: 31527875
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment (ART) interruption
Trial: 31528838
Drug: DASH diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DASH diet + Captopril (CAP) 25 mg
Trial: 31528838
Drug: Control (CON)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (CON) diet + Captopril (CAP) 25 mg
Trial: 31529018
Drug: Chemoradiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose (50.4 Gy to subclinical areas at risk and 63.0 Gy to the gross tumor and involved nodes, all given in 28 fractions) with concurrent docetaxel and capecitabine or fluorouracil
Trial: 31529070
Drug: Sodium depletion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium depletion test (oral administration of 40 mg of furosemide under low sodium diet)
Trial: 31529136
Drug: Lower limb
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower limb injections of abobotulinumtoxinA (1,000 U or 1,500 U)
Trial: 31529136
Drug: Lower and
RxNorm normalized name: Flower and weed pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower and upper limb injections of abobotulinumtoxinA (1,000 U lower limb, 500 U upper limb)
Trial: 31530099
Drug: Artificial intelligence
RxNorm normalized name: Intelence
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artificial intelligence fitting for cochlear implants
Trial: 31530099
Drug: Manual fitting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual fitting for cochlear implants
Trial: 31532724
Drug: Pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 mg/kg every 3 weeks for up to 24 months
Trial: 31532833
Drug: Pembrolizumab (anti-PD-1),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (anti-PD-1), administered as part of a Phase II clinical trial, with biopsies taken at baseline and 15-21 days post-dose.
Trial: 31533771
Drug: Denosumab administered
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab administered subcutaneously at 1 mg/kg body weight, dosage scheduled based on urinary deoxypyridinoline levels.
Trial: 31534013
Drug: AZD0156 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0156 (low doses)
Trial: 31534192
Drug: G-CSF +
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF + plerixafor (G-CSF + P)
Trial: 31534773
Drug: Maximal strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal strength training (MST) twice a week for 5 weeks, consisting of 3-4 sets of 4-6 repetitions at ≥85% of 1RM in a squat exercise.
Trial: 31534773
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) doing regular pre-season preparations.
Trial: 31537486
Drug: Ruxolitinib (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (15 mg twice a day) on a continuous 28-day cycle
Trial: 31537565
Drug: Lipid injectable
RxNorm normalized name: Lipid Injectable Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid injectable emulsion (two doses)
Trial: 31537565
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control (no treatment)
Trial: 31538078
Drug: Ramosetron (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron (0.3 mg IV)
Trial: 31538230
Drug: Lapatinib (750,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (750, 1000, 1250, or 1500 mg daily) plus Bortezomib (0.7, 1.0, 1.3, or 1.6 mg/m²)
Trial: 31538815
Drug: Dose-escalation followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-escalation followed by an expansion cohort
Trial: 31541204
Drug: Matched-related bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched-related bone marrow (BM) grafts with single-agent PTCy
Trial: 31541381
Drug: Cabozantinib 60-mg
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60-mg daily on a 21-day cycle + trastuzumab every 3 weeks (Cohort 1)
Trial: 31541381
Drug: Cabozantinib 60-mg
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60-mg daily on a 21-day cycle (Cohort 2)
Trial: 31541381
Drug: Cabozantinib 60-mg
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60-mg daily on a 21-day cycle (Cohort 3)
Trial: 31541381
Drug: Cabozantinib 60-mg
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60-mg daily on a 21-day cycle
Trial: 31541945
Drug: Oral panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral panobinostat plus chemotherapy (idarubicin and cytarabine)
Trial: 31541945
Drug: Idarubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin and cytarabine (chemotherapy)
Trial: 31544817
Drug: MEDI4276 (antibody-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4276 (antibody-drug conjugate)
Trial: 31544947
Drug: Treatment (surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (surgery or medical treatment)
Trial: 31545113
Drug: Selinexor in
RxNorm normalized name: Product containing selinexor in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor in combination with decitabine
Trial: 31548621
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering treatment based on absolute cardiovascular risk
Trial: 31548863
Drug: Strategies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategies to manage stress and promote healthy pregnancy targets (e.g., prenatal care)
Trial: 31549155
Drug: 30-mg oral
RxNorm normalized name: dacomitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mg oral dose of primaquine (PQ)
Trial: 31549262
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bleeding risk scores and frailty scales
Trial: 31551193
Drug: SCTE-AI 75
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTE-AI 75 mg once weekly for 6 weeks, adjusted to 50 mg or 100 mg as needed.
Trial: 31551193
Drug: SCTE-AI 75
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTE-AI 75 mg once weekly for 6 weeks, adjusted to maintain T trough levels.
Trial: 31551349
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg OXi4503
Trial: 31551349
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg OXi4503
Trial: 31551349
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg OXi4503
Trial: 31551376
Drug: HCV Treatment
RxNorm normalized name: THCV
DrugBank: Tetrahydrocannabivarin (DB11755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV Treatment as Prevention (TasP) in Tayside, Scotland
Trial: 31551902
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no specific treatment other than psychoeducation, n=46
Trial: 31552641
Drug: Ipragliflozin 50-mg
RxNorm normalized name: canagliflozin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 50-mg tablet once daily for 24 weeks
Trial: 31553487
Drug: Dasatinib at
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib at 50 mg daily
Trial: 31553639
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with cisplatin and fluorouracil followed by concurrent chemoradiotherapy (CCR) with three cycles of cisplatin.
Trial: 31553639
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with cisplatin and fluorouracil followed by concurrent chemoradiotherapy (CCR) with two cycles of cisplatin (amended treatment).
Trial: 31555109
Drug: tDCS (anodal;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS (anodal; F3, cathodal, Fp2, 2A, 20 min) twice daily for five consecutive days
Trial: 31555487
Drug: (Neo) adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Neo) adjuvant chemotherapy
Trial: 31555522
Drug: Apatinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (250 mg per day)
Trial: 31556778
Drug: Home pregnancy
RxNorm normalized name: Home Pregnancy Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home pregnancy test G
Trial: 31558424
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg orally once a day for 7 to 21 days preoperatively, resumed postoperatively in 28-day cycles.
Trial: 31558424
Drug: Neratinib (preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (preoperative and postoperative administration).
Trial: 31558467
Drug: Ublituximab (NHL:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ublituximab (NHL: 900 mg; CLL: 600 or 900 mg) + Umbralisib (800 or 1200 mg)
Trial: 31558469
Drug: GSI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSI treatment
Trial: 31558469
Drug: GSI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSI treatment in MM tumor-bearing NOD/SCID/γc-/- mice
Trial: 31558469
Drug: Short-term GSI
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term GSI administration to MM patients
Trial: 31558479
Drug: INVAC-1 (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INVAC-1 (100, 400, and 800 μg) administered intradermally followed by electroporation or by Tropis, a needle-free injection system
Trial: 31558626
Drug: Lung cancer
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung cancer screening by low-dose computed tomography (LDCT)
Trial: 31558670
Drug: ORH-2014 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORH-2014 5 mg
Trial: 31558670
Drug: ORH-2014 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORH-2014 10 mg
Trial: 31558670
Drug: ORH-2014 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORH-2014 15 mg
Trial: 31558804
Drug: Ixazomib-thalidomide-dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib-thalidomide-dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) for eight cycles followed by ixazomib maintenance for one year
Trial: 31558804
Drug: Ixazomib maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib maintenance therapy
Trial: 31560055
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment (oseltamivir)
Trial: 31560741
Drug: E/C/F/TAF (150/150/200/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/C/F/TAF (150/150/200/10 mg once daily)
Trial: 31560741
Drug: E/C/F/TDF (150/150/200/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/C/F/TDF (150/150/200/300 mg once daily)
Trial: 31560935
Drug: SM08502 (CLK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM08502 (CLK inhibitor), orally administered
Trial: 31562530
Drug: Intranasal inoculation
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal inoculation with nonattenuated, wild-type Bordetella pertussis strain B1917; dose escalated from 10^3 to 10^5 colony-forming units.
Trial: 31562530
Drug: Azithromycin administered
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin administered from Day 14.
Trial: 31562873
Drug: Robot-assisted gait
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted gait training and physical therapy
Trial: 31563412
Drug: Cetuximab-RT plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab-RT plus avelumab (10 mg/kg Q2W + 4 months maintenance)
Trial: 31563880
Drug: Regional anesthesia
RxNorm normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional anesthesia (RA) administered within 7 days after injury
Trial: 31563880
Drug: No regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No regional anesthesia (RA) administered
Trial: 31564038
Drug: Conventional imaging
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional imaging (computed tomography and somatostatin receptor scintigraphy)
Trial: 31566105
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with low-density lipoprotein cholesterol ≥1 g/L
Trial: 31566438
Drug: CCR2 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CCR2 antagonist (CCR2A)
Trial: 31566438
Drug: Combined CCR2
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined CCR2 antagonist (CCR2A) and angiotensin-converting enzyme inhibitor (ACEi)
Trial: 31567472
Drug: Kaolin-maximum rate
RxNorm normalized name: Kaolin
DrugBank: Kaolin (DB01575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaolin-maximum rate of thrombus generation using G (K-MRTGG)
Trial: 31567472
Drug: Functional fibrinogen-maximum
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional fibrinogen-maximum rate of thrombus generation using G (FF-MRTGG)
Trial: 31567573
Drug: Intra-operative fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-operative fentanyl dosing
Trial: 31570103
Drug: Current-metformin-users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current-metformin-users
Trial: 31570103
Drug: Never-metformin-users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Never-metformin-users
Trial: 31570103
Drug: Prediabetic never-metformin-users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediabetic never-metformin-users
Trial: 31570488
Drug: Eltrombopag initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag initiated at 50 mg/day, maximum 150 mg/day
Trial: 31570517
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg daily on days 4 to 10 of each 14-day cycle with mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin)
Trial: 31570781
Drug: G-CSF +
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF + plerixafor (G + P)
Trial: 31570781
Drug: G-CSF +
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF + plerixafor + chemotherapy (G + P + C)
Trial: 31570822
Drug: HRDetect-high patients
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRDetect-high patients on adjuvant chemotherapy